{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:01:52Z","timestamp":1784854912072,"version":"3.55.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bladder cancer (Bca) remains a major genitourinary malignancy with unmet needs in immunotherapy optimization. Despite advancements in immune checkpoint inhibitors (ICIs), challenges persist, including low response rates and drug resistance. Emerging evidence links tumor cell senescence to immunotherapy efficacy, yet predictive biomarkers are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We integrated genomic sequencing of real-world Bca patients receiving low-dose paclitaxel combined with immunotherapy to identify differentially expressed genes (DEGs) between responders and non-responders. By intersecting DEGs with senescence-related gene sets (SRGs), we derived senescence-related DEGs (SRDEGs) and constructed a senescence-immunotherapy model (SIM) via TCGA-based multi-regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The SIM, validated across three independent cohorts, demonstrated superior prognostic accuracy for overall survival (OS) compared to clinical parameters. High SIM scores correlated with immunosuppressive tumor microenvironments (TME). Drug sensitivity analysis revealed differential responses to cisplatin and paclitaxel between SIM subgroups. Critically, real-world validation confirmed SIM\u2019s predictive power for immunotherapy response. Multi-omics profiling further highlighted PPIL3 as a hub gene driving senescence and suppressing proliferation. <jats:italic>In vitro<\/jats:italic> experiments showed elevated expression of PPIL3 facilitated the concentration of senescence markers (SA-\u03b2-gal) and inhabited tumor cell proliferation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study establishes SIM as a dual-purpose tool for survival prediction and immunotherapy stratification, and suggested that PPIL3 could be a therapeutic target to enhance the efficacy of Bca by regulating senescence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1613056","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:10:18Z","timestamp":1750911018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Senescence-associated signature based on immunotherapy response sequencing reveals PPIL3 as target for bladder cancer treatment and prognosis prediction"],"prefix":"10.3389","volume":"16","author":[{"given":"Kaixuan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaipeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"114805","DOI":"10.1016\/j.ab.2022.114805","article-title":"Detection of ADAM15 in urine from patients with bladder cancer","volume":"654","author":"Gruba","year":"2022","journal-title":"Analytical Biochem"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40779-025-00599-y","article-title":"Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046","volume":"12","author":"Feng","year":"2025","journal-title":"Mil Med Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus calmette-gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with bacillus calmette-gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.11172","article-title":"An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of human recurrent bladder cancer","volume":"19","author":"Naito","year":"2020","journal-title":"Oncol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"Of4","DOI":"10.1158\/2159-8290.CD-NB2020-049","article-title":"Avelumab outduels supportive care for urothelial cancer","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet (London England)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal transduction targeted Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-019-0739-0","article-title":"Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression","volume":"12","author":"Wu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12964-024-01776-7","article-title":"The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0122","article-title":"Tumor microenvironment complexity: emerging roles in cancer therapy","volume":"72","author":"Swartz","year":"2012","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3122","article-title":"The promise of targeting macrophages in cancer therapy","volume":"23","author":"Brown","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/med.2019.39.issue-1","article-title":"Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target","volume":"39","author":"Oca\u00f1a","year":"2019","journal-title":"Medicinal Res Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/med.2015.35.issue-2","article-title":"Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures","volume":"35","author":"Sun","year":"2015","journal-title":"Medicinal Res Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.11.004","article-title":"Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0528","article-title":"Senescence rewires microenvironment sensing to facilitate antitumor immunity","volume":"13","author":"Chen","year":"2023","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-024-04867-8","article-title":"Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J Trans Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v11.6","article-title":"Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1","volume":"11","author":"Zhou","year":"2021","journal-title":"Clin Trans Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2009.0083","article-title":"ConsensusCluster: a software tool for unsupervised cluster discovery in numerical data","volume":"14","author":"Seiler","year":"2010","journal-title":"Omics: J Integr Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinf (Oxford England)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0962280219856238","article-title":"Adaptive lasso for the Cox regression with interval censored and possibly left truncated data","volume":"29","author":"Li","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13148-019-0730-1","article-title":"Statistical predictions with glmnet","volume":"11","author":"Engebretsen","year":"2019","journal-title":"Clin Epigenet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics: J Integr Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.xcrm.2020.100020","article-title":"Senescence inflames the pancreatic tumor microenvironment","volume":"1","author":"Petroni","year":"2020","journal-title":"Cell Rep Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/cac2.12591","article-title":"Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment","volume":"44","author":"Zhang","year":"2024","journal-title":"Cancer Commun (London England)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101614","DOI":"10.1016\/j.redox.2020.101614","article-title":"Time-dependent replicative senescence vs. disturbed flow-induced pre-mature aging in atherosclerosis","volume":"37","author":"Dominic","year":"2020","journal-title":"Redox Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"0612","DOI":"10.34133\/research.0612","article-title":"The common hallmarks and interconnected pathways of aging, circadian rhythms, and cancer: implications for therapeutic strategies","volume":"8","author":"Wang","year":"2025","journal-title":"Res (Wash D C)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.redox.2024.103208","article-title":"Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives","volume":"73","author":"Li","year":"2024","journal-title":"Redox Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.euo.2024.04.020","article-title":"Phase 2 study of preoperative tislelizumab in combination with low-dose nab-paclitaxel in patients with muscle-invasive bladder cancer","volume":"8","author":"Wu","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3321","article-title":"Phase II pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer","volume":"31","author":"Qie","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020346","article-title":"Beyond tumor suppression: senescence in cancer stemness and tumor dormancy","volume":"9","author":"Triana-Mart\u00ednez","year":"2020","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0475-x","article-title":"BMP6-induced modulation of the tumor micro-milieu","volume":"38","author":"Stieglitz","year":"2019","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171556","article-title":"The VEGFA(156)b isoform is dysregulated in senescent endothelial cells and may be associated with prevalent and incident coronary heart disease","volume":"132","author":"Latorre","year":"2018","journal-title":"Clin Sci (London England: 1979)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82492","article-title":"FN1 mRNA 3'-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3'-UTR-let-7i-5p-THBS1 axis","volume":"13","author":"Pan","year":"2023","journal-title":"Theranostics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.07.018","article-title":"The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease","volume":"43","author":"de Almeida","year":"2015","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2020.1822636","article-title":"Identification of spliceosome components pivotal to breast cancer survival","volume":"18","author":"An","year":"2021","journal-title":"RNA Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311421","article-title":"Tumour CD274 (PD-L1) expression and T cells in colorectal cancer","volume":"66","author":"Masugi","year":"2017","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-024-01465-0","article-title":"p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells","volume":"26","author":"Majewska","year":"2024","journal-title":"Nat Cell Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7150\/thno.52199","article-title":"CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3","volume":"11","author":"Feng","year":"2021","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.11431","article-title":"HOXB5 promotes the proliferation and invasion of breast cancer cells","volume":"11","author":"Lee","year":"2015","journal-title":"Int J Biol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7150\/thno.57659","article-title":"Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation","volume":"11","author":"He","year":"2021","journal-title":"Theranostics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Espinosa-Carrasco","year":"2024","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.010","article-title":"Immune cell triads reprogram exhausted CD8(+) T cells for effective tumor elimination","volume":"42","author":"Lise","year":"2024","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural killer group 2D receptor and its ligands in cancer immune escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2455","article-title":"CAF-derived IL6 and GM-CSF cooperate to induce M2-like TAMs-letter","volume":"25","author":"Iorio","year":"2019","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41419-019-1435-2","article-title":"Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1935","article-title":"Immunotherapy of MSI cancer: facts and hopes","volume":"30","author":"Wilbur","year":"2024","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.v5.9","article-title":"Oncogenic SLC2A11-MIF fusion protein interacts with polypyrimidine tract binding protein 1 to facilitate bladder cancer proliferation and metastasis by regulating mRNA stability","volume":"5","author":"Cheng","year":"2024","journal-title":"MedComm (2020)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"107302","DOI":"10.1016\/j.phrs.2024.107302","article-title":"Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review","volume":"206","author":"Tuo","year":"2024","journal-title":"Pharmacol Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2233","article-title":"NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer","volume":"83","author":"Xie","year":"2023","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J immunotherapy Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613056\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:10:20Z","timestamp":1750911020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613056\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1613056"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1613056","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"1613056"}}